Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma

Cancer Medicine

Volumn 4, Issue 7, 2015, Pages 977-988

  Allen Rhoades, Wendy ^a   Kurenbekova, Lyazat ^a   Satterfield, Laura ^a   Parikh, Neha ^a   Fuja, Daniel ^a   Shuck, Ryan L ^a   Rainusso, Nino ^a   Trucco, Matteo ^a   Barkauskas, Donald A ^b   Jo, Eunji ^a   Ahern, Charlotte ^a   Hilsenbeck, Susan ^a   Donehower, Lawrence A ^a   Yustein, Jason T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biomarker; MicroRNA; Mouse model; Osteosarcoma; Plasma

Indexed keywords

DOXORUBICIN; MICRORNA; MICRORNA 205 5P; MICRORNA 214; MICRORNA 335 5P; PLACEBO; UNCLASSIFIED DRUG; TRANSCRIPTOME; TUMOR MARKER;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; FEMALE; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; MOUSE MODEL; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ALLOGRAFT; ANIMAL; BLOOD; BONE NEOPLASMS; CANCER STAGING; DISEASE MODEL; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; KNOCKOUT MOUSE; MORTALITY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; YOUNG ADULT;

ADOLESCENT; ADULT; ALLOGRAFTS; ANIMALS; BIOMARKERS, TUMOR; BONE NEOPLASMS; CHILD; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICRORNAS; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TRANSCRIPTOME; YOUNG ADULT;

EID: 85006202049     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.438     Document Type: Article

References (23)

1. Mirabello, L., R. J. Troisi, and S. A. Savage. 2009. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 115:1531-1543.
2. Calin, G. A., and C. M. Croce. 2006. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6:857-866.
3. Cortez, M. A., C. Ivan, P. Zhou, X. Wu, M. Ivan, and G. A. Calin. 2010. microRNAs in cancer: from bench to bedside. Adv. Cancer Res. 108:113-157.
4. Cortez, M. A., C. Bueso-Ramos, J. Ferdin, G. Lopez-Berestein, A. K. Sood, and G. A. Calin. 2011. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8:467-477.
5. Kosaka, N., H. Iguchi, and T. Ochiya. 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101:2087-2092.
6. Ng, E. K., W. W. Chong, H. Jin, E. K. Lam, V. Y. Shin, J. Yu, et al. 2009. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58:1375-1381.
7. Selth, L. A., S. Townley, J. L. Gillis, A. M. Ochnik, K. Murti, R. J. Macfarlane, et al. 2011. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int. J. Cancer 131: 652-661.
8. Zhao, S., L. Kurenbekova, Y. Gao, A. Roos, C. J. Creighton, P. Rao, et al. 2015. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene 12. doi: 10.1038/onc.2014.429. [Epub ahead of print].
9. Cochrane, R. L., S. H. Clark, A. Harris, and B. E. Kream. 2007. Rearrangement of a conditional allele regardless of inheritance of a Cre recombinase transgene. Genesis 45:17-20.
10. Dumble, M. L., L. A. Donehower, and X. Lu. 2003. Generation and characterization of p53 mutant mice. Methods Mol. Biol. 234:29-49.
11. Andersen, C. L., J. L. Jensen, and T. F. Orntoft. 2004. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64:5245-5250.
12. Golde, W. T., P. Gollobin, and L. L. Rodriguez. 2005. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim. (NY) 34:39-43.
13. Yao, C., S. Wu, D. Li, H. Ding, Z. Wang, Y. Yang, et al. 2012. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro. Mol. Oncol. 6:392-404.
14. Kaminskas, L. M., V. M. McLeod, B. D. Kelly, C. Cullinane, G. Sberna, M. Williamson, et al. 2012. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Mol. Pharm. 9:422-432.
15. Keith, W. N., P. J. Mee, and R. Brown. 1990. Response of mouse skin tumors to doxorubicin is dependent on carcinogen exposure. Cancer Res. 50:6841-6847.
16. Pritchard, C. C., H. H. Cheng, and M. Tewari. 2012. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13:358-369.
17. Ouyang, L., P. Liu, S. Yang, S. Ye, W. Xu, and X. Liu. 2013. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Med. Oncol. 30:340.
18. Qin, A. Y., X. W. Zhang, L. Liu, J. P. Yu, H. Li, S. Z. Wang, et al. 2013. MiR-205 in cancer: an angel or a devil? Eur. J. Cell Biol. 92:54-60.
19. Xu, Z., and T. Wang. 2014. miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1. Biochem. Biophys. Res. Commun. 449: 190-195.
20. Wang, Z., H. Cai, L. Lin, M. Tang, and H. Cai. 2014. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. Pediatr. Blood Cancer 61:206-210.
21. Zhang, J., Q. Tu, L. F. Bonewald, X. He, G. Stein, J. Lian, et al. 2011. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J. Bone Miner. Res. 26:1953-1963.
22. Guerit, D., D. Philipot, P. Chuchana, K. Toupet, J. M. Brondello, M. Mathieu, et al. 2013. Sox9-regulated miRNA-574-3p inhibits chondrogenic differentiation of mesenchymal stem cells. PLoS ONE 8:e62582.
23. Cai, Y., T. Cai, and Y. Chen. 2014. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J. Cell. Biochem. 115:625-631.